Balchem Corporation — Q1 2012 Form 10-Q
Business context and reporting period: The filing covers the three months ended March 31, 2012; comparative results are for Q1 2011. Balchem develops and sells specialty ingredients and products across Specialty Products, Food, Pharma & Nutrition, and Animal Nutrition & Health. Dollar amounts below are in thousands, except per-share data.
Financial performance and position
- Revenue: $76,203, up 4.4% from $73,008. Domestic sales rose to $50,878 from $46,018; foreign sales declined to $25,325 from $26,990.
- Earnings: Gross profit was $21,158, up 1.8%; gross margin declined to 27.8% from 28.5%. Operating earnings were $13,675, up 2.8%, with operating margin of 17.9% versus 18.2%. Net earnings rose 4.0% to $9,268. Diluted EPS was $0.31 versus $0.30; basic EPS was $0.32 versus $0.31.
- Cash flow: Operating cash flow was $12,655 versus $9,671. Capital expenditures were $1,401 versus $1,786, implying operating cash flow less capital expenditures of $11,254. Cash increased $6,510 during the quarter to $121,291.
- Liquidity: Working capital was $156,785, up from $144,827 at year-end 2011. Current assets were $182,846 and current liabilities $26,061.
- Debt: Balance-sheet debt comprised $1,096 current and $89 long-term at March 31. The company had no borrowings on its $6,000 domestic revolver or €3,000 European revolver. Both facilities matured May 31, 2012; management expected renewal in the normal course. The European term loan carried a 1.57% rate and matured May 1, 2014.
- Other balance-sheet items: Total assets were $278,121 and stockholders’ equity was $243,450. Dividends paid were $5,237; the company repurchased 23,212 shares for an average $41.53 per share.
Material changes and segment trends
- Specialty Products: Sales rose 8.5% to $12,257; segment earnings increased to $4,729. Growth was mainly from ethylene oxide sterilization sales and propylene oxide fumigation, partly offset by raw-material cost pressure.
- Food, Pharma & Nutrition: Sales fell 2.7% to $10,737, chiefly because of weaker food-market volumes. Human choline sales increased $1,067 and partly offset the decline. Segment earnings rose to $2,709.
- Animal Nutrition & Health: Sales increased 5.0% to $53,209. Specialty ingredient sales grew 30%, supported by improved dairy economics and volume gains; global feed-grade choline sales fell about 5%. Segment earnings declined 2.7% to $6,237, primarily due to higher petrochemical input costs. Industrial applications represented about 28.7% of segment sales.
- Company-wide cost of sales rose faster than revenue, reducing gross margin. Operating expenses were nearly unchanged at $7,483. The effective tax rate declined to 32.3% from 33.4%, primarily due to state tax apportionment changes.
Outlook, risks and contingencies
- No quantified earnings or revenue guidance was provided. Management expected operations to generate sufficient cash to fund working capital and necessary capital investment, and said it was pursuing acquisition candidates.
- Management cited raw-material pricing and foreign-currency movements as market risks; the company manages exposures where possible through pricing and operational measures. It had no derivatives or hedging instruments. A 100-basis-point interest-rate change on period-end borrowings was estimated to change annual interest expense and cash flow by approximately $12.
- Management expected both revolving credit facilities to be renewed. The $1,498 of cash held by foreign subsidiaries was intended to remain invested abroad; repatriation could result in additional U.S. taxes.
- Environmental matters include ongoing discussions with New York regulators about a former drum site; any further action was expected likely to involve monitoring, historically costing less than $5 annually. The company believes remediation at its Verona, Missouri site is complete; the prior owner is responsible for any further Superfund remedy, with indemnification protections described in the filing.
- Management believed pending litigation and claims would not materially affect financial position, results, or liquidity. Unrecognized tax benefits were approximately $2,057, and the company did not anticipate a material change over the next 12 months. The filing reported no material change in risk factors, no significant internal-control changes, and effective disclosure controls.
Important facts for investors to verify
- Whether the two revolving credit facilities were renewed after their May 31, 2012 maturity dates.
- Whether rising raw-material costs and lower gross margins persisted, especially in Animal Nutrition & Health.
- Whether segment growth, including human choline and animal specialty ingredients, continued to offset weaker Food, Pharma & Nutrition food-market volumes and lower feed-grade choline sales.
- Future cash deployment, including acquisitions, capital spending, dividends, and share repurchases; foreign cash repatriation and potential tax consequences.
- Developments in the New York environmental matter, tax exposures, and any changes in contingent liabilities.